ALK-Abelló A/S (CPH:ALK.B)
237.20
-0.40 (-0.17%)
Jul 21, 2026, 11:18 AM CET
ALK-Abelló Revenue
ALK-Abelló had revenue of 1.77B DKK in the quarter ending March 31, 2026, with 16.36% growth. This brings the company's revenue in the last twelve months to 6.56B, up 14.94% year-over-year. In the year 2025, ALK-Abelló had annual revenue of 6.31B with 14.00% growth.
Revenue (ttm)
6.56B
Revenue Growth
+14.94%
P/S Ratio
8.02
Revenue / Employee
2.38M
Employees
2,759
Market Cap
52.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.31B | 775.00M | 14.00% |
| Dec 31, 2024 | 5.54B | 713.00M | 14.78% |
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | 3.49B | 217.00M | 6.63% |
| Dec 31, 2019 | 3.27B | 359.00M | 12.32% |
| Dec 31, 2018 | 2.92B | 5.00M | 0.17% |
| Dec 31, 2017 | 2.91B | -95.00M | -3.16% |
| Dec 31, 2016 | 3.01B | 436.00M | 16.97% |
| Dec 31, 2015 | 2.57B | 136.00M | 5.59% |
| Dec 31, 2014 | 2.43B | 189.00M | 8.42% |
| Dec 31, 2013 | 2.24B | -101.00M | -4.31% |
| Dec 31, 2012 | 2.35B | -3.00M | -0.13% |
| Dec 31, 2011 | 2.35B | 189.00M | 8.75% |
| Dec 31, 2010 | 2.16B | 224.00M | 11.58% |
| Dec 31, 2009 | 1.94B | 151.00M | 8.46% |
| Dec 31, 2008 | 1.78B | 132.00M | 7.99% |
| Dec 31, 2007 | 1.65B | 133.00M | 8.76% |
| Dec 31, 2006 | 1.52B | 30.00M | 2.01% |
| Aug 31, 2006 | 1.49B | 272.00M | 22.35% |
| Aug 31, 2005 | 1.22B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 327.80B |
| Coloplast | 28.05B |
| H. Lundbeck | 25.52B |
| Genmab | 25.29B |
| Demant | 22.97B |
| GN Store Nord | 16.60B |
| Zealand Pharma | 9.24B |
| Embla Medical | 6.21B |
ALK-Abelló News
- 5 weeks ago - EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis - GlobeNewsWire
- 5 weeks ago - Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap - GlobeNewsWire
- 7 weeks ago - Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff - GlobeNewsWire
- 7 weeks ago - ALK-Abello initiated with a Buy at Berenberg - TheFly
- 2 months ago - ALK-Abelló Quarterly report: Q1 2026 - Filings
- 2 months ago - ALK-Abelló Slides: Q1 2026 - Filings
- 2 months ago - ALK-Abelló Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - ALK-Abelló Quarterly report: Q1 2026 - Filings